AUPH
Aurinia Pharmaceuticals Inc.NASDAQHealthcare$15.61+0.90%ClosedMarket Cap: $2.08B
As of 2026-04-06
Valuation
P/E (TTM)
7.23
PEG
0.00
P/B
3.70
P/S
7.52
EV/EBITDA
14.91
DCF Value
$-48.01
FCF Yield
6.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
88.5%
Operating Margin
37.1%
Net Margin
101.5%
ROE
70.4%
ROA
38.2%
ROIC
15.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $77.1M | 89.0% | $33.2M | $210.8M | $1.53 | — |
| FY 2025 | $283.1M | 88.5% | $104.9M | $287.2M | $2.07 | — |
| Q3 2025 | $73.5M | 88.4% | $29.7M | $31.6M | $0.23 | — |
| Q2 2025 | $70.0M | 89.8% | $20.1M | $21.5M | $0.15 | — |
| Q1 2025 | $62.5M | 86.3% | $21.8M | $23.3M | $0.16 | — |
| Q4 2024 | $59.9M | 90.7% | $-1.7M | $1.4M | $0.01 | — |
| FY 2024 | $235.1M | 88.0% | $-4.7M | $5.8M | $0.04 | — |
| Q3 2024 | $67.8M | 91.1% | $11.7M | $14.3M | $0.10 | — |
| Q2 2024 | $57.2M | 84.4% | $-1.5M | $722.0K | $0.01 | — |
| Q1 2024 | $50.3M | 84.6% | $-10.7M | $-10.7M | $-0.07 | — |
| Q4 2023 | $45.1M | 88.0% | $-29.7M | $-26.9M | $-0.19 | — |
| FY 2023 | $175.5M | 91.9% | $-91.7M | $-78.0M | $-0.54 | — |